Hikma Pharmaceuticals

Hikma Pharmaceuticals, a UK-headquartered Pharmaceutical Preparation Manufacturing company, has disclosed its carbon emissions and climate commitments.

In 2025, Hikma Pharmaceuticals reported total emissions of approximately 863.1 million kg CO2e. This included Scope 1 emissions of about 46.7 million kg CO2e, Scope 2 emissions (location-based) of around 91.1 million kg CO2e, and Scope 3 emissions of approximately 827.2 million kg CO2e. Key contributors to Scope 3 emissions were purchased goods and services (about 651.0 million kg CO2e), capital goods (about 57.6 million kg CO2e), and use of sold products (about 59.5 million kg CO2e).

For 2024, the company's total emissions were approximately 860.7 million kg CO2e. This comprised Scope 1 emissions of roughly 38.5 million kg CO2e, Scope 2 emissions (location-based) of about 87.2 million kg CO2e, and Scope 3 emissions totalling around 861.8 million kg CO2e. Major Scope 3 categories included purchased goods and services (about 681.2 million kg CO2e) and capital goods (around 46.6 million kg CO2e).

Looking back to 2023, Hikma Pharmaceuticals' total emissions were approximately 837.0 million kg CO2e. Scope 1 emissions were about 43.8 million kg CO2e, Scope 2 emissions (location-based) were around 83.5 million kg CO2e, and Scope 3 emissions stood at roughly 836.0 million kg CO2e. Purchased goods and services contributed significantly to Scope 3 emissions (about 717.8 million kg CO2e).

The company aims to reduce its Scope 1 and 2 GHG emissions by 25% by 2030, using a 2020 baseline. Furthermore, Hikma Pharmaceuticals has set a long-term goal to achieve net-zero emissions by 2050. Between 2017 and 2020, the company achieved a 4% reduction in reported Scope 1 and 2 GHG emissions.